

INFORMED CONSENT

(New York I allow my s	ample DNA and information	Sused for commercial products. Yes No SIGNATURE OF AUTHORIZED REPRESENTATIVE PRINT NAME DATE	
(New York I allow my s	ample DNA and information	used for commercial products. Yes No	
(New York I allow my s	ample DNA and information	used for commercial products. Yes No	
(New York I allow my s	ample DNA and information		
(New York I allow my s	ample DNA and information		
	Condent o specimens will be	to be used for research. ☐ Yes ☐ No	
		ur samples and information to be used: e destroyed after 60 days unless checked yes)	
		I have been given a copy of this consent form. I have been given the chance to can ask other questions at any time. I want to have this genetic test done.	
after testing unless you specifi	cally authorizes their use in research	ch or commercial applications (see check boxes below).	
hat can affect how you will respond to a variety of medications. The test is highly accurate (> 99% specificity and sensitivity) but rare variants in other reas of these genes that could affect drug responsiveness may not be detected. Lesults from this test(s) are treated with complete confidentiality and reports rendered only to you and your physician. Your samples will be destroyed			
PATIENT:	TIENT: ur doctor has ordered one or more of the following tests: - PGxOnePlus™ test is a DNA sequencing assay used to identify DNA variants in 50 genes		
PRINTED NAME			
PHYSICIAN SIGNATURE		DATE	
		the DNA testing is not a substitute for clinical monitoring.	
By signing below, I confirm that to the patient. The patient has t	t I have explained the purpose of the	nis test, the procedures, and the benefits, risks, and limitations that are involved in t tions about this test and offered genetic counseling. The healthcare provider unders	
Group (DPWG) and the FDA's work group guidance and will be used to help predict how the patient may respond to drugs. Based on the results of the est, I may make changes to the type of drug that I prescribe, or to the amount of a drug that I prescribe to the patient. I understand that the PGxOnePlus est is highly accurate.			
Group (DPWG) and the FDA's	mmendations of the Clinical Pharm		
purpose of this test is to guide and variants based on the reco Group (DPWG) and the FDA's	ng to be performed. This test looks	s for mutations in genes that are known to be associated with metabolism of drug- ig faster and optimize drug therapy. I confirm that this genetic test panel includes nacogenetics Implementation Consortium (CPIC) and Dutch Pharmacogenetics W	